• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨标志物在血液透析患者低转换型骨营养不良诊断中的应用

Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.

作者信息

Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F

机构信息

Pathophysiology and Hypertension Unit, La Sapienza University, Rome, Italy.

出版信息

Nephrol Dial Transplant. 1998 Sep;13(9):2294-302. doi: 10.1093/ndt/13.9.2294.

DOI:10.1093/ndt/13.9.2294
PMID:9761512
Abstract

BACKGROUND

Renal osteodystrophy includes a number of low and high turnover bone histologic patterns which require a bone biopsy for their full identification. The role of intact PTH and several classical and more recent bone markers in the non-invasive diagnosis of renal bone disease in patients with CRF in HD requires further definition since available published data are limited.

METHODS

In addition to intact PTH, alkaline phosphatase (AP) and osteocalcin (BGP), bone alkaline phosphatase isoenzyme (BALP), tartrate resistant acid phosphatase (TRAP), C-terminal cross-linked peptide of collagen type 1 (ICTP) and deoxypyridinoline (DPD) were measured in the serum of 41 patients on haemodialysis, subjected at the same time to transiliac bone biopsy for histomorphometric, histodynamic and aluminium histochemical examination. Histodynamic evaluation following double tetracycline label, was carried out in 37 patients. The patients had no evidence of active cytolytic and cholestatic liver disease and a history of very limited aluminium exposure.

RESULTS

The patients had differing degrees of hyper-parathyroidism, with intact PTH ranging from normal to very elevated levels. Serum values of the markers BGP, ICTP and DPD, normally excreted through the kidneys, were on average very high. The correlation coefficients of the humoral parameters vs dynamic variables, such as BFR/BS, were high. The highest values were: intact PTH 0.798, AP 0.900, BALP 0.891, ICTP 0.807. The patients, grouped in low turnover osteodystrophy (LTO; 9), mixed osteodystrophy (MO; 9) and prevalent hyperparathyroidism (HP; 23), showed significant difference in the levels of most humoral and static and dynamic parameters (ANOVA). Bone aluminium histochemistry was negative in all cases. Discrimination of LTO patients from the other groups by humoral parameters, at the highest value of accuracy, showed 100% sensitivity and 93.7% specificity with a cut-off of 12.9 ng/ml for BALP; 88.9% sensitivity and 93.7% specificity with a cut-off of 21.5 ng/ml for DPD, and 88.9% sensitivity and 90.6% specificity with a cut-off of 79.7 pg/ml for intact PTH. The other markers had lower values. A standardized z-score approach for evaluation of all humoral parameters was also carried out. Using all variables, a correct classification of MO/HP and of LTO was possible in 93.8 and 88.9% of the cases, respectively. Predictive power was 96.8 and 80%, respectively for MO/HP and LTO. When the only variables used were intact PTH and BALP, a correct classification of MO/HP and LTO was possible in 90.6% and 88.9%, respectively. Predictive value of MO/HP was 96.7% and for LTO 72.7%. Predictive values using PTH and AP were 96.3% and 57.2%, respectively.

CONCLUSION

Intact PTH and several relatively new bone markers are of certain value in the non-invasive diagnosis of renal osteodystrophy. However some of the humoral markers carry the same quality of information and the use of intact PTH and BALP may be adequate in the discrimination of bone histologic patterns. In cases exempt from liver disease, PTH and AP may be used as a less costly alternative. Bone biopsy could be chiefly limited to cases with borderline humoral values and to all those with a suspected aluminium overload.

摘要

背景

肾性骨营养不良包括多种低转换和高转换骨组织学模式,需要进行骨活检才能完全明确。由于现有公开数据有限,完整甲状旁腺激素(PTH)以及几种经典和最新的骨标志物在慢性肾衰竭(CRF)血液透析(HD)患者肾性骨病的无创诊断中的作用需要进一步明确。

方法

除了检测完整PTH、碱性磷酸酶(AP)和骨钙素(BGP)外,还检测了41例血液透析患者血清中的骨碱性磷酸酶同工酶(BALP)、抗酒石酸酸性磷酸酶(TRAP)、Ⅰ型胶原C末端交联肽(ICTP)和脱氧吡啶啉(DPD),同时对这些患者进行了髂骨骨活检,以进行组织形态计量学、组织动力学和铝组织化学检查。37例患者进行了双四环素标记后的组织动力学评估。这些患者没有活动性溶细胞性和胆汁淤积性肝病的证据,且铝暴露史非常有限。

结果

患者存在不同程度的甲状旁腺功能亢进,完整PTH水平从正常到极高。通常经肾脏排泄的标志物BGP、ICTP和DPD的血清值平均非常高。体液参数与动态变量如骨形成率/骨表面积(BFR/BS)之间的相关系数很高。最高值分别为:完整PTH 0.798、AP 0.900、BALP 0.891、ICTP 0.807。将患者分为低转换骨营养不良(LTO;9例)、混合性骨营养不良(MO;9例)和显著甲状旁腺功能亢进(HP;23例),大多数体液、静态和动态参数水平存在显著差异(方差分析)。所有病例的骨铝组织化学检查均为阴性。通过体液参数将LTO患者与其他组区分开来,在最高准确度时,BALP以12.9 ng/ml为临界值,敏感性为100%,特异性为93.7%;DPD以21.5 ng/ml为临界值,敏感性为88.9%,特异性为93.7%;完整PTH以79.7 pg/ml为临界值,敏感性为88.9%,特异性为90.6%。其他标志物的值较低。还对所有体液参数进行了标准化z评分评估。使用所有变量时,分别有93.8%和88.9%的病例能够正确分类MO/HP和LTO。MO/HP和LTO的预测能力分别为96.8%和80%。当仅使用完整PTH和BALP作为变量时,分别有90.6%和88.9%的病例能够正确分类MO/HP和LTO。MO/HP的预测值为96.7%,LTO的预测值为72.7%。使用PTH和AP的预测值分别为96.3%和57.2%。

结论

完整PTH和几种相对较新的骨标志物在肾性骨营养不良的无创诊断中具有一定价值。然而,一些体液标志物携带相同质量的信息,完整PTH和BALP的联合使用可能足以区分骨组织学模式。在无肝病的情况下,PTH和AP可作为成本较低的替代方法。骨活检主要可限于体液值临界的病例以及所有疑似铝过载的病例。

相似文献

1
Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.骨标志物在血液透析患者低转换型骨营养不良诊断中的应用
Nephrol Dial Transplant. 1998 Sep;13(9):2294-302. doi: 10.1093/ndt/13.9.2294.
2
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.透析治疗的慢性肾脏病患者骨转换标志物和骨组织学的诊断准确性。
Am J Kidney Dis. 2016 Apr;67(4):559-66. doi: 10.1053/j.ajkd.2015.06.023. Epub 2015 Aug 25.
3
Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.透析前及血液透析患者的肾性骨营养不良:组织学模式及完整甲状旁腺激素诊断预测性的比较
Nephron. 2002 May;91(1):103-11. doi: 10.1159/000057611.
4
Urinary deoxypyridinoline excretion for the evaluation of bone turnover in chronic renal failure.尿脱氧吡啶啉排泄量用于评估慢性肾衰竭患者的骨转换情况。
Am J Nephrol. 2000 Jul-Aug;20(4):283-90. doi: 10.1159/000013602.
5
Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy.血清胶原合成与降解肽段在透析肾性骨营养不良中的诊断价值
Nephrol Dial Transplant. 1995;10(1):52-8.
6
Serum osteoprotegerin and renal osteodystrophy.血清骨保护素与肾性骨营养不良
Nephrol Dial Transplant. 2002 Feb;17(2):233-8. doi: 10.1093/ndt/17.2.233.
7
Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.骨转换率低与非低的血液透析患者的骨碱性磷酸酶同工型:一项诊断试验研究
Am J Kidney Dis. 2015 Jul;66(1):99-105. doi: 10.1053/j.ajkd.2015.02.323. Epub 2015 Apr 2.
8
Bone alkaline phosphatase isoenzyme in renal osteodystrophy.
Nephrol Dial Transplant. 1996;11 Suppl 3:43-6. doi: 10.1093/ndt/11.supp3.43.
9
PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.甲状旁腺激素1-84和甲状旁腺激素“7-84”在肾性骨病的无创诊断中的应用
Am J Kidney Dis. 2002 Aug;40(2):348-54. doi: 10.1053/ajkd.2002.34519.
10
Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients.低水平的骨源性血清碱性磷酸酶:血液透析患者动力缺失性骨病的良好标志物。
Nephrol Dial Transplant. 1996 Jun;11(6):1065-72.

引用本文的文献

1
Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.慢性肾脏病中的动力缺失性骨病:作为诊断和治疗靶点的潜在生物标志物的荟萃分析与叙述性综述
Ren Fail. 2025 Dec;47(1):2530162. doi: 10.1080/0886022X.2025.2530162. Epub 2025 Jul 16.
2
Risk factors and clinical prediction models for osteoporosis in pre-dialysis chronic kidney disease patients.透析前慢性肾脏病患者骨质疏松的危险因素及临床预测模型。
Ren Fail. 2024 Dec;46(2):2361802. doi: 10.1080/0886022X.2024.2361802. Epub 2024 Jun 14.
3
Bone Disease in Chronic Kidney Disease and Kidney Transplant.
慢性肾脏病和肾移植中的骨骼疾病
Nutrients. 2022 Dec 29;15(1):167. doi: 10.3390/nu15010167.
4
Bone Turnover Markers: Basic Biology to Clinical Applications.骨转换标志物:基础生物学与临床应用。
Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031.
5
Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.碱性磷酸酶:慢性肾脏病心血管和矿物质骨骼疾病治疗靶点的老朋友。
Nutrients. 2022 May 19;14(10):2124. doi: 10.3390/nu14102124.
6
Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study.骨对甲状旁腺激素的反应性与接受血液透析的患者中甲状旁腺激素降低药物的使用呈负相关:一项横断面研究。
BMC Nephrol. 2021 Aug 9;22(1):275. doi: 10.1186/s12882-021-02482-z.
7
The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).饮食干预对慢性肾脏病-矿物质和骨异常(CKD-MBD)的影响。
Nutrients. 2021 Jun 16;13(6):2065. doi: 10.3390/nu13062065.
8
The Non-invasive Diagnosis of Bone Disorders in CKD.CKD 中的骨代谢紊乱的非侵入性诊断。
Calcif Tissue Int. 2021 Apr;108(4):512-527. doi: 10.1007/s00223-020-00781-5. Epub 2021 Jan 4.
9
Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.碳酸镧对新进入血液透析患者骨标志物和骨密度的影响。
J Bone Miner Metab. 2019 Nov;37(6):1075-1082. doi: 10.1007/s00774-019-01018-8. Epub 2019 Jun 18.
10
Laboratory aspects and clinical utility of bone turnover markers.骨转换标志物的实验室检测及临床应用
EJIFCC. 2018 Jul 11;29(2):117-128. eCollection 2018 Jul.